Mesenchymal Precursor Cells 25 M not checked
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Acute Myocardial Infarction
- Main trialPhase 2
- “This was a double-blind, randomized, placebo-controlled study that was designed to enroll a total of 225 participants with de novo anterior wall acute ST-segment elevation myocardial infarction (STEMI) due to a lesion of the left anterior descending coronary artery undergoing percutaneous coronary intervention (PCI). Eligible participants were to be enrolled and undergo revascularization of the culprit left anterior descending (LAD) coronary artery. The interventional procedure included as dose ranging assessment of intracoronary (IC) delivery of MPC or placebo infused into the stented…”In the company’s words, NCT01781390 on ClinicalTrials.gov
Other drugs for Acute Myocardial Infarction
- InclisiranNovartis · Phase 3
- ZalunfibanCeleCor Therapeutics · Phase 3
- SGC001Beijing Sungen Biomedical Technology Co., Ltd · Phase 2
- UMSC01Ever Supreme Bio Technology Co., Ltd. · Phase 2
- XolatrypNyrada Pty Ltd · Phase 2
- NL005Beijing Northland Biotech. Co., Ltd. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 6 Apr 2021 | Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026